<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234975</url>
  </required_header>
  <id_info>
    <org_study_id>PUER-02-003</org_study_id>
    <nct_id>NCT00234975</nct_id>
  </id_info>
  <brief_title>Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score</brief_title>
  <official_title>Evaluation of Clinical Response and Safety in HIV Positive Subjects Co-infected With Hepatitis C Treated With a Kaletra Containing HAART Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate clinical response and safety of a Kaletra containing
      antiretroviral treatment regimen in HIV positive subjects with HCV coinfection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measure</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 16 and Week 24</time_frame>
    <description>Changes in liver functions enzyme.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 16 and Week 24</time_frame>
    <description>Changes in HIV viral load, CD4/CD8 cell count, and Hepatitis C viral load</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>HCV +</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV -</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir</intervention_name>
    <description>400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator</description>
    <arm_group_label>HCV +</arm_group_label>
    <arm_group_label>HCV -</arm_group_label>
    <other_name>ABT-378, lopinavir/ritonavir, Kaletra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV positive.

          -  At least 18 years of age.

          -  Does not exhibit evidence of acute illness (especially any acute liver disease, except
             hepatitis C)

          -  Subject has not been treated for an active opportunistic infection within 30 days of
             the baseline visit.

          -  Subject Has a Karnofsky Score greater than or equal to 70.

          -  Subject does not require and agrees not to take, for the duration of the study, any of
             the following medications that are contraindicated with Kaletra: astemizole,
             terfenadine, midazolam, triazolam, cisapride, certain ergot derivatives (ergotamine,
             dihydroergotamine, ergonovine, and methylergonovine), pimozide, propafenone and
             flecainide. Rifampin, a potent enzyme inducer, should not be administered with the
             study medication, because of the possibility of significant decreases in Kaletra
             concentration during concurrent administration.

          -  The subject agrees not to take any medication, including over-the-counter medicine,
             alcohol, recreational drugs or herbal preparations without the knowledge and
             permission of the principal investigator.

          -  Subject had laboratory testing within the previous three months and the most recent
             testing demonstrates all of the following: Hemoglobin&gt; 8.0 g/dL; absolute neutrophil
             count &gt; 750 cells/mL; Platelet count &gt; 20,000/mL; ALT or AST &lt;/=10 x upper limit of
             normal (ULN); Creatinine&lt; 1.5 x ULN; Triglycerides &lt;/=750 mg/dL.

          -  Subjects have no evidence of grade III or IV adverse event or laboratory abnormality
             (except for LFTs).

        Exclusion Criteria:

        No exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos R Rivera-Vazquez, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4118</name>
      <address>
        <city>Bayamon</city>
        <zip>00960</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4119</name>
      <address>
        <city>Bayamon</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6298</name>
      <address>
        <city>Juana Diaz</city>
        <zip>00795</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6284</name>
      <address>
        <city>Las Piedras</city>
        <zip>00771</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4101</name>
      <address>
        <city>Mayaguez</city>
        <zip>00680</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4116</name>
      <address>
        <city>Playa de Ponce</city>
        <zip>00731</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4117</name>
      <address>
        <city>Ponce</city>
        <zip>00717-1563</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4099</name>
      <address>
        <city>Ponce</city>
        <zip>00731</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4086</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00926</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4080</name>
      <address>
        <city>San Juan</city>
        <zip>00908</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4100</name>
      <address>
        <city>Santurce</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <last_update_submitted>January 2, 2013</last_update_submitted>
  <last_update_submitted_qc>January 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lopinavir</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Phase 4</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

